Abpro
We have a very unique T-cell engager Bi-specific antibody platform.
Our COVID-19 neutralization antibody project is in phae 2 clinical tiral.
We have about 10 different Bi-specific projects in pre-clinical stage focusing on oncology, autoimmune and ophthomology.
We are looking for China partners to codevelop the Bi-specific antibodies.
We are also raising the capital to set up the CHina subsidiary.
You can add my wechat: elite8800
John Xu
SVPAbsenteeism. Presenteeism.
Solopreneur. Addiction recovery. Interventions. Family assistance. Organization and HR mentorships.
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Virtual meetings Host, Guest, Panelist, Master of Ceremonies.
Mr. Leo Petrilli
Addiction Recovery Coach AND MentorAbveris Inc.
Abveris is a Massachusetts-based company that provides industry-leading solutions for therapeutic and reagent antibody developements. We have built a strong reputation for our ability to deliver outstanding science. Based on our proprietary hyperimmune mouse models, DiversimAb mouse, and a Beacon-based single B cell screening platform, we have custom-built gene-to-antibody solutions to support development efforts for therapeutic antibodies against difficult targets such as GPCR, ion channels, glycan targets. Abveris is rapidly expanding its antibody discovery capabilities and geographical presence to work with more emerging biotech to discover therapeutics for novel targets.
Gary Ng
Director of MarketingAchelios Therapeutics
Achelios Therapeutics, Inc., based in RTP Carolina, is a privately held specialty biopharmaceutical company whose core competency is the reformulation of non-steroidal anti-inflammatory drug (NSAID) molecules that have historically been used to treat pain and inflammation by topical application.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Our proprietary formulation allows for fast and enhanced delivery of active agents across human skin into subdermal tissues.
Achelios is currently developing:
OTC 1% diclofenac topical formulation for the treatment of pain and inflammation. Our product shows improved efficacy, better compliance, photoprotection, and dossing schedule vs. Voltaren® ANDA to be submitted in 4Q 2021.
The next product in development is a superior 3% diclofenac formulation being developed for the prescription market for acute and chronic pain. These product has demonstrated greater efficacy, safety and photostability vs. other topical gels available globally. Our product has also shown efficacy as an opioid-spearing agent in the treatment of pain.
Dr. Crist Frangakis
President & ceoAcon Pharmaceuticals Inc
ACON Pharmaceuticals Inc. (ACON Pharma) is a specialty pharmaceutical company and focuses on siRNA and mRNA nanoparticle delivery, 505(b)(2) NDA, and complex ANDA drug product development with its captive drug delivery system and technology platforms. Acon Pharma is a privately held corporation located in Princeton, New Jersey, USA. As a dynamic pharmaceutical company in a vibrant life science research region, Acon Pharma leverages the expertise and experience of highly skilled, multi-disciplinary workforce to accelerate the product development of complex drug delivery systems. The Company’s key managers were primarily educated in US with advanced degrees and trained in the pharmaceutical industry for many years, and have possessed deep professional knowledge, technical know-how, and extensive experiences in pharmaceutical product development.
We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.
We are currently raising 5 million dollar fund to support IND-enabling studies for our patented liposomal siRNA for treatment of pulmonary fibrosis and long-acting microsphere for treatment of schizophrenia. We are also developing delayed release nanoemulsion for osteoporosis, and sustained release gel for fungal infection.
Xudong Yuan
CEOAction Ventures
Venture Capital and fundraising for fast growing companies. Action means action.
Mr. Tony Ihander
FounderAdagene
Adagene, Inc. is a platform-driven, clinical-stage biopharmaceutical company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies. Adagene combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Its proprietary pipeline is comprised of novel immunotherapy programs. Adagene has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.
Mr. Alexander Goergen
Business DevelopmentAdverum Biotechnologies
Adverum Biotechnologies (Nasdaq: ADVM) is a clinical-stage gene therapy company targeting unmet medical needs in serious ocular and rare diseases. Adverum is advancing the clinical development of its novel gene therapy candidate, ADVM-022, as a one-time, intravitreal injection for the treatment of patients with wet age-related macular degeneration and diabetic macular edema. For more information, please visit www.adverum.com.